Valeritas (NSDQ:VLRX) said today that it began the process to register its wearable insulin delivery device, V-Go, in China.
The company noted that it signed an agreement with an unnamed contract research organization to work directly with the China National Drug Administration, in the hopes of winning regulatory approval for V-Go in China.
“The China market for V-Go is nothing short of enormous. We have now taken the first step to make the V-Go Wearable Insulin Delivery device available in China with the hope that it can become the insulin delivery method of choice for the millions of Chinese patients with type 2 diabetes,” president & CEO John Timberlake said in prepared remarks.
Earlier this year, Valeritas launched its insulin delivery device in Australia and New Zealand.
